[Preliminary study on antibacterial activity of recombinant fusion protein Pheromonicin-PA to Pseudomonas aeruginosa in vitro/in vivo].
OBJECTIVE
To prepare the engineering peptide Pheromonicin-P. aeruginosa (Ph-PA) and evaluate the antibactericidal activity of prepared Ph-PA against P. aeruginosa via in vitro/in vivo bactericidal assays.


METHODS
Ph-PA was purified by CM sepharose ion-exchange column. In vitro/in vivo bactericidal assays were performed to identify the antibactericidal activity of Ph-PA against P. aeruginosa.


RESULTS
In vitro and in vivo data showed that antibactericidal effects of Ph-PA, on molar basis, were approximately over 2200 times greater than that of piperacillin, and 220 times greater than that of ceftazidime against P. aeruginosa.


CONCLUSIONS
The Ph-PA may have potentially applied value as a novel kind of peptide antibiotics against P. aeruginosa infection.
Sun
Liang
L
Key Laboratory of Transplantation Engineering and Immunology, Ministry of Health, West China Hospital, Sichuan University, Chengdu 610041, China.
Zhang
Jie
J
Dai
Ping
P
Qin
Yan
Y
Qiu
Xiao-Qing
XQ
D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple / Q000187:drug effects; D004591:Electrophoresis, Polyacrylamide Gel; D004926:Escherichia coli / Q000187:drug effects / Q000254:growth & development; D005260:Female; D008297:Male; D051379:Mice; D008826:Microbial Sensitivity Tests; D010455:Peptides / Q000235:genetics* / Q000494:pharmacology*; D015202:Protein Engineering / Q000379:methods*; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000235:genetics*; D011993:Recombinant Fusion Proteins / Q000235:genetics* / Q000494:pharmacology*; D013045:Species Specificity
D000900:Anti-Bacterial Agents; D010455:Peptides; D011993:Recombinant Fusion Proteins